A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 8, 2011

Primary Completion Date

February 2, 2022

Study Completion Date

February 2, 2022

Conditions
Ovarian Cancer
Interventions
BIOLOGICAL

Vigil™

Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.

Trial Locations (7)

33401

Florida Cancer Specialists, West Palm Beach

75230

Mary Crowley Cancer Research Centers, Dallas

75246

Texas Oncology - Sammons Cancer Center, Dallas

76104

Texas Oncology - Fort Worth, Fort Worth

99202

Cancer Care Northwest, Spokane

03756

Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center, Lebanon

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gradalis, Inc.

INDUSTRY